Congress loves shaming CEOs. So why hasn’t pharma been put on the hot seat?

WASHINGTON — It’s a rite of passage for executives in the hot seat: get hauled before Congress, sit for bipartisan tirades, squirm in the face of difficult questioning.

Over the past six months, lawmakers have dragged in former Equifax CEO Richard Smith, Wells Fargo’s Tim Sloan, and Amtrak’s Richard Anderson. Facebook’s Mark Zuckerberg could be the next one up.

But drug makers, despite persistent concern over prices, have somehow managed to wriggle free from congressional testimony.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In